Neo Ivy Capital Management purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 65,786 shares of the biopharmaceutical company's stock, valued at approximately $702,000.
Other institutional investors have also modified their holdings of the company. OLD Second National Bank of Aurora purchased a new stake in shares of Amicus Therapeutics in the third quarter valued at about $26,000. Hazlett Burt & Watson Inc. raised its position in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,569 shares during the last quarter. Blue Trust Inc. lifted its stake in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new stake in Amicus Therapeutics during the 3rd quarter valued at $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Amicus Therapeutics during the 3rd quarter valued at $55,000.
Analyst Ratings Changes
Several analysts have recently issued reports on FOLD shares. Morgan Stanley reduced their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Guggenheim raised their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Cantor Fitzgerald boosted their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Finally, StockNews.com raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $17.63.
Read Our Latest Stock Report on FOLD
Amicus Therapeutics Trading Down 0.1 %
Shares of NASDAQ FOLD traded down $0.01 during trading on Thursday, hitting $10.15. 2,152,968 shares of the company traded hands, compared to its average volume of 2,713,919. The firm has a market capitalization of $3.03 billion, a P/E ratio of -29.85 and a beta of 0.60. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The company has a 50-day moving average price of $10.55 and a 200-day moving average price of $10.61. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57.
Insider Activity at Amicus Therapeutics
In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at $8,884,273.08. The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 30,401 shares of company stock worth $339,363. 2.20% of the stock is owned by insiders.
Amicus Therapeutics Company Profile
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Read More
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.